The ability of the commercial inertial measurement unit-based gait system in determining Parkinson's disease: A systematic review with meta-analysis of cross-sectional studies.
Jiahao Pan, Hui Tang
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis of cross-sectional studies assessed whether commercial inertial measurement unit (IMU)-based gait systems distinguish people with Parkinson’s disease (PD) from healthy controls. Nine studies included up to 571 people with PD and 470 controls. Overall gait variability was greater in the PD groups (Hedges’ g = 0.368, 95% CI 0.139-0.597). The primary analysis found no statistically significant overall difference in gait asymmetry. The authors describe the evidence as preliminary and note that group-level differences do not establish individual-level discrimination or clinical utility.
Key findings
- Overall gait variability was greater in PD than in healthy controls (Hedges’ g = 0.368, 95% CI 0.139-0.597).
- The multi-IMU subgroup showed greater gait variability (Hedges’ g = 0.397, 95% CI 0.221-0.574), but the between-subgroup difference was not statistically significant.
- The primary analysis found no statistically significant overall difference in gait asymmetry (Hedges’ g = 0.180, 95% CI -0.012-0.373).
Why it matters
Commercial IMU-based gait measures may capture group-level differences in gait variability associated with PD. However, a difference between group averages does not show that the systems can reliably classify individuals or provide clinically useful information. The findings therefore help distinguish promising measurement signals from evidence sufficient to establish diagnostic performance.
What to keep in mind
The evidence came from nine cross-sectional studies, and the multi-IMU prediction interval included null. The review notes that individual-level discrimination and clinical utility remain difficult to establish.